{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:30:19Z","timestamp":1794018619112,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1208\/s12249-021-02108-5","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T20:06:58Z","timestamp":1632946018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Primaquine Loaded Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), and Nanoemulsion (NE): Effect of Lipid Matrix and Surfactant on Drug Entrapment, in vitro Release, and ex vivo Hemolysis"],"prefix":"10.1208","volume":"22","author":[{"given":"Kai-Wei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendar","family":"Dudhipala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prit","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan D.","family":"Chaurasiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu L.","family":"Tekwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyajit","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"2108_CR1","unstructured":"World malaria report 2020: 20 years of global progress and challenges. World Health Organization; 2020."},{"issue":"9","key":"2108_CR2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1086\/424663","volume":"39","author":"JK Baird","year":"2004","unstructured":"Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39(9):1336\u201345.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2108_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1471-4922(03)00005-9","volume":"19","author":"JK Baird","year":"2003","unstructured":"Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol. 2003;19(3):115\u201320.","journal-title":"Trends Parasitol"},{"issue":"1","key":"2108_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/1475-2875-10-351","volume":"10","author":"D Fernando","year":"2011","unstructured":"Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10(1):351.","journal-title":"Malar J"},{"issue":"1","key":"2108_CR5","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1038\/s41467-019-11239-0","volume":"10","author":"G Camarda","year":"2019","unstructured":"Camarda G, Jirawatcharadech P, Priestley RS, Saif A, March S, Wong MHL, et al. Antimalarial activity of primaquine operates via a two-step biochemical relay. Nat Commun. 2019;10(1):3226.","journal-title":"Nat Commun"},{"issue":"1","key":"2108_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12936-019-2658-5","volume":"18","author":"PS Fasinu","year":"2019","unstructured":"Fasinu PS, Nanayakkara NPD, Wang YH, Chaurasiya ND, Herath HMB, McChesney JD, et al. Formation primaquine-5,6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes. Malar J. 2019;18(1):30.","journal-title":"Malar J"},{"issue":"3","key":"2108_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4269\/ajtmh.2006.75.402","volume":"75","author":"DR Hill","year":"2006","unstructured":"Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75(3):402\u201315.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"2108_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1208\/s12249-010-9563-0","volume":"12","author":"S Das","year":"2011","unstructured":"Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62\u201376.","journal-title":"AAPS PharmSciTech"},{"issue":"7","key":"2108_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.addr.2007.05.006","volume":"59","author":"DJ Hauss","year":"2007","unstructured":"Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59(7):667\u201376.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"2108_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2174\/156720111795767906","volume":"8","author":"A Rahman","year":"2011","unstructured":"Rahman A, Harwansh R, Mirza A, Hussain S, Hussain A. Oral lipid based drug delivery system (LBDDS): formulation, characterization and application: a review. Curr Drug Deliv. 2011;8(4):330\u201345.","journal-title":"Curr Drug Deliv"},{"issue":"21","key":"2108_CR11","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1016\/0006-2952(82)90633-5","volume":"31","author":"P Pirson","year":"1982","unstructured":"Pirson P, Steiger R, Trouet A. The disposition of free and liposomally encapsulated antimalarial primaquine in mice. Biochem Pharmacol. 1982;31(21):3501\u20137.","journal-title":"Biochem Pharmacol"},{"issue":"1\u20132","key":"2108_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijpharm.2005.01.026","volume":"295","author":"D Bhadra","year":"2005","unstructured":"Bhadra D, Yadav A, Bhadra S, Jain N. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm. 2005;295(1\u20132):221\u201333.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"2108_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijpharm.2005.07.015","volume":"303","author":"AM Dierling","year":"2005","unstructured":"Dierling AM, Cui Z. Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy. Int J Pharm. 2005;303(1\u20132):143\u201352.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"2108_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijpharm.2007.06.035","volume":"347","author":"KK Singh","year":"2008","unstructured":"Singh KK, Vingkar SK. Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. Int J Pharm. 2008;347(1\u20132):136\u201343.","journal-title":"Int J Pharm"},{"key":"2108_CR15","first-page":"3865","volume":"9","author":"WN Omwoyo","year":"2014","unstructured":"Omwoyo WN, Ogutu B, Oloo F, Swai H, Kalombo L, Melariri P, et al. Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles. Int J Nanomedicine. 2014;9:3865\u201374.","journal-title":"Int J Nanomedicine"},{"key":"2108_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejpb.2016.10.021","volume":"110","author":"G Zoubari","year":"2017","unstructured":"Zoubari G, Staufenbiel S, Volz P, Alexiev U, Bodmeier R. Effect of drug solubility and lipid carrier on drug release from lipid nanoparticles for dermal delivery. Eur J Pharm Biopharm. 2017;110:39\u201346.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"2108_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1208\/s12249-008-9178-x","volume":"10","author":"A Azeem","year":"2009","unstructured":"Azeem A, Rizwan M, Ahmad FJ, Iqbal Z, Khar RK, Aqil M, et al. Nanoemulsion components screening and selection: a technical note. AAPS PharmSciTech. 2009;10(1):69\u201376.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"2108_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"RH Muller","year":"2000","unstructured":"Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161\u201377.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"2108_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1208\/s12249-011-9665-3","volume":"12","author":"S Li","year":"2011","unstructured":"Li S, Ji Z, Zou M, Nie X, Shi Y, Cheng G. Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine. AAPS PharmSciTech. 2011;12(3):1011\u20138.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"2108_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","volume":"13","author":"P Costa","year":"2001","unstructured":"Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123\u201333.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"2108_CR21","first-page":"217","volume":"67","author":"S Dash","year":"2010","unstructured":"Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217\u201323.","journal-title":"Acta Pol Pharm"},{"key":"2108_CR22","doi-asserted-by":"crossref","unstructured":"Evans BC, Nelson CE, Yu SS, Beavers KR, Kim AJ, Li H, et al. Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J Vis Exp. 2013(73):e50166.","DOI":"10.3791\/50166"},{"key":"2108_CR23","doi-asserted-by":"crossref","unstructured":"Chong W-T, Tan C-P, Cheah Y-K, B. Lajis AF, Habi Mat Dian NL, Kanagaratnam S, et al. Optimization of process parameters in preparation of tocotrienol-rich red palm oil-based nanoemulsion stabilized by Tween80-Span 80 using response surface methodology. PloS one. 2018;13(8):e0202771.","DOI":"10.1371\/journal.pone.0202771"},{"key":"2108_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.colsurfa.2014.01.066","volume":"447","author":"G Lv","year":"2014","unstructured":"Lv G, Wang F, Cai W, Zhang X. Characterization of the addition of lipophilic Span 80 to the hydrophilic Tween 80-stabilized emulsions. Colloids Surf, A. 2014;447:8\u201313.","journal-title":"Colloids Surf, A"},{"issue":"31","key":"2108_CR25","doi-asserted-by":"publisher","first-page":"9285","DOI":"10.1021\/la502312n","volume":"30","author":"JC Athas","year":"2014","unstructured":"Athas JC, Jun K, McCafferty C, Owoseni O, John VT, Raghavan SR. An effective dispersant for oil spills based on food-grade amphiphiles. Langmuir. 2014;30(31):9285\u201394.","journal-title":"Langmuir"},{"issue":"3","key":"2108_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/157016311796799062","volume":"8","author":"RH Muller","year":"2011","unstructured":"Muller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol. 2011;8(3):207\u201327.","journal-title":"Curr Drug Discov Technol"},{"issue":"15","key":"2108_CR27","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1016\/j.biomaterials.2004.07.050","volume":"26","author":"KY Win","year":"2005","unstructured":"Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(15):2713\u201322.","journal-title":"Biomaterials"},{"key":"2108_CR28","doi-asserted-by":"crossref","unstructured":"Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. Journal of controlled release. 1987;5(1):37\u201342.","DOI":"10.1016\/0168-3659(87)90035-6"},{"key":"2108_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2012.09.028","volume":"64","author":"J Siepmann","year":"2012","unstructured":"Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2012;64:163\u201374.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2108_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0378-5173(97)00222-6","volume":"157","author":"C Schwarz","year":"1997","unstructured":"Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm. 1997;157(2):171\u20139.","journal-title":"Int J Pharm"},{"key":"2108_CR31","doi-asserted-by":"crossref","unstructured":"Kumar H, Gothwal A, Khan I, Nakhate KT, Alexander A, Singh V, et al. Galactose-anchored gelatin nanoparticles for primaquine delivery and improved pharmacokinetics: a biodegradable and safe approach for effective antiplasmodial activity against p. Falciparum 3d7 and in vivo hepatocyte targeting. Molecular pharmaceutics. 2017;14(10):3356\u201369.","DOI":"10.1021\/acs.molpharmaceut.7b00376"}],"updated-by":[{"DOI":"10.1208\/s12249-021-02171-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000}}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-02108-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-021-02108-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-02108-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T07:02:51Z","timestamp":1640070171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-021-02108-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2108"],"URL":"https:\/\/doi.org\/10.1208\/s12249-021-02108-5","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1208\/s12249-021-02171-y","URL":"https:\/\/doi.org\/10.1208\/s12249-021-02171-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"240"}}